India sees sizeable improvement in finished dosage reputation and growth ahead of CPhI India 2021 Read more
Biocon Biologics and Viatris’s Semglee preferred on Express Scripts’ largest formulary in US Read more
“Make in India” to fuel four-times growth in biosimilars and vaccines by 2026: CII-Kearney report Read more
Inter-changeable designation for Semglee in the US is a milestone achievement for Biocon Biologics Read more